search

Active clinical trials for "Osteoporosis"

Results 81-90 of 1458

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia®...

Postmenopausal Women With Osteoporosis

This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis

Active21 enrollment criteria

Effects of OsteoStrong vs. Individually Adapted and Combined Training on Bone Health

OsteoporosisOsteopenia3 more

The aim of this clinical trial is to investigate the effect of the OsteoStrong training method and the Individually Adapted and Combined Training on the bone health of older women with high fracture risk. Additionally, the aim is also to explore the participants' experiences of each training method. Participants will be randomised to either treatment arm A (OsteoStrong) or treatment arm B (Individually Adapted and Combined Training). Participants in both groups will train for nine months. Treatment arm A will train individually once a week and treatment arm B will train in a group twice a week. Both groups will have a training instructor who will supervise and give training instructions. Researchers will compare the groups to see the effects of the training methods on the participants' bone health among other outcome measures. The participants will be tested at baseline and post-intervention (9 months later).

Active15 enrollment criteria

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

OsteoporosisPostmenopausal

This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, and PK profiles of AVT03 and Prolia in postmenopausal women with osteoporosis. After the screening activities, eligible subjects were randomized in a 1:1 ratio to receive either AVT03 60 mg or Prolia® 60 mg, administered as a subcutaneous (s.c.) injection on Day 1 and Day 180 (Month 6). At Month 12, subjects in AVT03 treatment group will receive a third dose of AVT03 60 mg administered s.c. while subjects in Prolia® treatment group will be re-randomized in a 1:1 ratio to receive either Prolia 60 mg or AVT03 60 mg on Day 365 (Month 12), administered as a subcutaneous injection. Afterwards, the subjects will be followed until the End of Study (EoS) Visit at Month 18 (ie, 6 months after the last dose at Month 12). 32 clinical sites are now participating in this study and total of 532 patients have been randomized. Ccountries : Bulgaria, Czech Republic, Georgia, Poland, South Africa.

Active16 enrollment criteria

Comparative Antiresorptive Efficacy Discontinuation of Denosumab

OsteoporosisPostmenopausal1 more

Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene. Denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-B ligand (RANKL). Denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued. This study will help us determine the optimal duration and relative efficacy of two oral antiresorptive medications that are FDA-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.

Active14 enrollment criteria

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis...

Postmenopausal Women With Osteoporosis

This study is a Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporosis

Active14 enrollment criteria

Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49

Osteoporosis Risk

Summary Purpose: To examine the effect of the education program to increase osteoporosis awareness given to women aged 18-49. Method: The research is planned to be carried out in the Women's Culture and Education Centers of Ankara Altındağ Municipality. Altındağ Municipality has 24 Women's Culture and Education Centers in 24 different neighborhoods with a total of 60000 registered members (https://www.altindag.bel.tr/#!kadin_egitim_kultur_merkezleri). It is planned that the research will be conducted in the first three centers where the most members between the ages of 18-49 from 24 Women's Culture and Education Centers are registered. In case the sufficient number of samples required for the conduct of the research could not be reached, it was planned to include the fourth center where women between the ages of 18-49 registered the most. The number of women to be included in the sample of the study was determined as 60 women, 30 of which were in the control group. Intervention and control groups will be assigned to the groups by randomization method. The data collection tools to be used in the research are the Introductory Information Form, the Osteoporosis Health Belief Scale and the Osteoporosis Awareness Scale. In the implementation of the research, a one-to-one training program will be held to increase awareness of osteoporosis. It is planned that the one-to-one education program to increase awareness of osteoporosis will be held every 2 weeks in 3 sessions in total and each session will last approximately 40-50 minutes.

Enrolling by invitation13 enrollment criteria

Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users

Glucocorticoid-induced Osteoporosis

Glucocorticoid (GC) is the main stay of treatment of many rheumatic diseases but is also an important cause of secondary osteoporosis. The long-term use of GCs increases the risk of fragility fracture at a much higher bone mineral density (BMD) than postmenopausal osteoporosis, indicating an additional deleterious effect of GC on bone quality. An increased relative risk of vertebral and hip fractures is demonstrated in chronic GC users, with fracture risk proportional to the daily dose of GC. Other studies have also confirmed that intermittent use of high-dose GC and the cumulative GC dose was associated with an augmented risk of osteoporotic fracture. Romosozumab (ROMO) is a humanized monoclonal antibody against sclerostin. The landmark RCT has demonstrated efficacy of ROMO (210mg subcutaneously monthly) over placebo in reducing vertebral fractures by 73% at 12 months in 7180 postmenopausal women with osteoporosis of the hip at entry. Another RCT has demonstrated efficacy of ROMO in reducing vertebral and hip fractures in 4093 post-menopausal women at month 24. There are no data regarding the efficacy of ROMO in GC-induced osteoporosis. Comparative study on the efficacy of ROMO and denosumab in post-menopausal osteoporosis is also not yet available in the literature. This prompts the current pilot study to compare the efficacy of ROMO with denosumab in high-risk patients receiving long-term GCs.

Active10 enrollment criteria

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal...

Osteoporosis

The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.

Active48 enrollment criteria

The Erlangen Fitness and Prevention Study (EFOPS).

OsteoporosisOsteopenia1 more

The study determines the long-term effect of exercise on osteoporotic fracture risk. Since actually no controlled supervised exercise study exceeds the time frame of 4 years, knowledge concerning the long-term effect of exercise on fractures and fracture-risk factors is scarce. Within the Erlanger Fitness and Osteoporosis Study (EFOPS, an ongoing controlled exercise study with currently 16 years of supervised exercise with 45-50 osteopenic, early-postmenopausal women in exercise and sedentary control group each, the investigators therefore focus on overall-fractures, Bone Mineral Density and falls.

Active6 enrollment criteria

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen...

Breast CancerOsteoporosis

RATIONALE: Gathering information over time from bone density and laboratory tests of women with breast cancer treated with triptorelin and tamoxifen or exemestane may help the study of breast cancer in the future. PURPOSE: This clinical trial is studying changes in bone mineral density in women with breast cancer treated with triptorelin and tamoxifen or exemestane on protocol IBC SG-25-02 (TEXT).

Active16 enrollment criteria
1...8910...146

Need Help? Contact our team!


We'll reach out to this number within 24 hrs